United States Patent 6,645,466 Landscape: What Claims Cover and Where Risk Concentrates for Dry Powder Inhaler Ordered Mixtures with Magnesium Stearate Moisture Resistance
Executive summary. U.S. Patent 6,645,466 claims a dry powder inhalation formulation built as an ordered mixture of (i) a non-inhalable-size carrier powder, (ii) a finely divided inhalable-size active selected from formoterol, ipratropium, tiotropium and salts, and (iii) magnesium stearate at 0.1 to 2% w/w (with narrower dependent bands to 0.25 to 1% and 0.4 to 0.8%) positioned as providing improved resistance to moisture. The claim set narrows further to specific carriers (glucose, lactose monohydrate, trehalose) and to an optional subcomponent: micronized lactose monohydrate with ≥50% of particles ≤10 μm. Business implication: the enforceable “core” is not just the drug plus lactose, but the combination architecture (carrier particle-size class + inhalable active size class + ordered mixture + magnesium stearate amount tied to moisture performance). A design-around that changes any one of those anchors (active particle sizing classing, ordered-mixture architecture, magnesium stearate identity/amount, or carrier system) is the principal risk lever.
What is the scope of U.S. Patent 6,645,466 claims and what is the core inventive concept?
Claim 1 is the breadth anchor. It is a three-component dry powder inhalation (DPI) formulation where the critical limitations are:
- “Ordered mixture” architecture
- Two particle-size regimes
- carrier: “particles of noninhalable particle size”
- active: “inhalable particle size”
- Active selection: formioterol, ipratropium, tiotropium and pharmaceutically acceptable salts
- Magnesium stearate: 0.1 to 2% w/w, “based on total weight of the formulation,” present in an amount sufficient to provide improved resistance to moisture
Core enforceable elements (practically read as claim pillars)
| Claim pillar |
How it constrains scope |
Practical litigation trigger |
| Ordered mixture |
Requires a specific mixing/arrangement concept, not merely co-milling |
Evidence of manufacturing/mixing sequence and ordering steps |
| Carrier particle size is non-inhalable |
Limits carrier to larger/non-inhalable particle classes |
Particle-size distributions in powder characterization |
| Active particle size is inhalable |
Limits active to an inhalable-class size regime |
PSD testing plus definition of “inhalable” in the patent record |
| Active is from a closed list |
Limits actives to formoterol, ipratropium, tiotropium and salts |
Identity of the active ingredient used in the accused product |
| Magnesium stearate identity and dosing |
Requires magnesium stearate at 0.1–2% w/w |
Ingredient list and quantitative assay |
| Magnesium stearate provides moisture resistance |
Functional performance tie to dosing |
Moisture uptake/shelf-life testing framed to the patent’s rationale |
Which actives and salts does U.S. Patent 6,645,466 cover for dry powder inhalers?
Claim 1 active group is a defined list:
- Formioterol / formoterol (spelling in claim set)
- Ipratropium
- Tiotropium
- Pharmaceutically acceptable salts of those actives
Claim 7 and dependent claims explicitly list salts:
- formoterol fumarate
- formoterol tartrate
- ipratropium bromide
- tiotropium bromide
Salt coverage impact
Because the claims name specific salts in the salt-dependent branch, products using those exact salts align more directly with that dependent scope. Salt changes (to other acceptable salts) move infringement analysis back to the broader “pharmaceutically acceptable salts” language in Claim 1.
What carriers does U.S. Patent 6,645,466 protect, and how narrow is the “carrier system” limitation?
Claim 4 (carrier genus) includes:
- monosaccharides
- disaccharides
- sugar alcohols
- polylactic acid
- cyclodextrin
Claim 5 (carrier species) narrows to:
- glucose
- lactose monohydrate
- trehalose
Claim 12 (example constraint under the active/salt branch) further narrows to:
- active: formoterol fumarate
- carrier: lactose monohydrate
- magnesium stearate: 0.4 to 0.8% w/w
Enforceability read-through
- The broadest carrier coverage is large (Claim 4), but infringement still requires the non-inhalable size-class carrier plus ordered mixture plus the magnesium stearate dosing tied to moisture resistance.
- The most litigation-relevant “easy mapping” is lactose monohydrate-based DPI products where moisture-related performance is attributed to magnesium stearate inclusion at the claimed ranges.
How do the magnesium stearate limits define “what is protected” for moisture resistance?
The patent ties magnesium stearate to a functional objective: improved resistance to moisture, with explicit dosing ranges.
Magnesium stearate quantitative claim bands
| Claim |
Magnesium stearate range (w/w, total formulation basis) |
Claim language effect |
| Claim 1 |
0.1 to 2% |
Broad core |
| Claim 2 |
0.25 to 1% |
Middle range narrowing |
| Claim 3 |
0.4 to 0.8% |
Narrowest dependent dosing window |
| Claim 8 |
0.25 to 1% |
Salt-branch narrowing aligned to Claim 7 |
| Claim 9 |
0.4 to 0.8% |
Salt-branch narrowing aligned to Claim 7 |
| Claim 12 / 15 |
0.4 to 0.8% |
Example formulations tied to formoterol + lactose |
Design-around pressure points
- Stepping outside 0.1–2%: direct avoidance of Claim 1’s dosage band.
- Changing magnesium stearate to a different lubricant: breaks Claim 1 identity element.
- Using the same lubricant but at a nearby dose (e.g., slightly below 0.1% or above 2%): avoids the claim dose band, but may raise other patents (not addressed here).
- Replacing magnesium stearate while preserving moisture resistance does not matter for literal infringement; infringement turns on the claim elements.
What does “ordered mixture” mean in claim scope and how does it affect infringement analysis?
Claim 1 requires “a dry powder formulation … in the form of an ordered mixture”.
From an IP enforcement standpoint, “ordered mixture” is the most structurally non-routine limitation because typical DPI product manufacturing is described in terms of mixing sequences and blend order, not always as “ordered mixture.” The claim’s enforceability will likely hinge on:
- Whether the accused product uses a mixing step that places components in an ordered or layered relationship (as opposed to random blending).
- Whether the patent record defines “ordered mixture” in a consistent technical way (e.g., ordered deposition, staged addition, or particle layering).
Practically, this is where product-quality records and batch manufacturing documentation become decisive: they provide the evidence chain to show (or rebut) the “ordered mixture” feature.
Does U.S. Patent 6,645,466 cover micronized lactose monohydrate, and what are the particle-size specifics?
Claim 6 adds an optional component under Claim 1:
- “further comprising particles of micronized lactose monohydrate wherein at least 50% of the particles have a maximum particle size of 10 μm.”
Claim 13 mirrors this under the Claim 7 salt/active branch.
Why the numeric threshold matters
- The “≥50% ≤10 μm” language is a crisp quantitative discriminator.
- A formulation that avoids the micronized component, or has a shifted PSD profile (e.g., fewer than 50% at ≤10 μm), reduces literal alignment with these dependent claims.
Note: Claim 6 is dependent on Claim 1, so to infringe Claim 6 you must satisfy Claim 1 first, then meet this specific micronized-lactose PSD feature.
How do the dependent claims build narrower protection for specific formoterol plus lactose formulations?
Claim 12 is a specific “example-type” narrowing:
- active: formoterol fumarate
- carrier: lactose monohydrate
- magnesium stearate: 0.4 to 0.8% w/w
Claim 15 is the analogous narrower form under Claim 14:
- active: formoterol fumarate
- carrier: lactose monohydrate
- magnesium stearate: 0.4 to 0.8% w/w
These dependent claims compress the claim space to products with:
- formoterol fumarate (not necessarily tartrate),
- lactose monohydrate carrier,
- and the mid-to-narrow magnesium stearate dosing window.
For licensing or litigation strategy, these dependents matter because they define tighter infringement “matches” when an accused formulation uses the exact dose band and carrier.
What is the maximum active loading range protected by U.S. Patent 6,645,466?
Claim 14 sets:
- active present in amount 0.1 to 5% w/w (based on total formulation)
Claim 15 anchors that range within a specific product structure:
- formoterol fumarate + lactose monohydrate + magnesium stearate 0.4–0.8%
This matters for products that use much higher or much lower active wt% in the blend.
What generic entry risks exist for reformulations outside the claimed architecture?
Literal infringement risk map (based on claim element substitution)
| Product change |
Likely effect vs Claim 1 |
Residual risk |
| Use a different active (not formoterol/ipratropium/tiotropium) |
Avoids active identity element |
Other patents may cover different actives, not assessed here |
| Use magnesium stearate dose outside 0.1–2% |
Avoids dose element |
Other patents may cover lubricant systems |
| Replace magnesium stearate with another lubricant |
Avoids identity element |
Potential overlap with other formulation patents |
| Use carrier where carrier is inhalable-size |
Avoids “noninhalable carrier size class” |
If still inhalable/noninhalable borderline, PSD proof matters |
| Use active particle size outside inhalable regime |
Avoids “inhalable size class” |
PSD and characterization are key |
| Drop ordered-mixture processing (random blend) |
Potentially avoids ordered-mixture limitation |
Depends on how ordered is construed |
| Swap out lactose monohydrate for another carrier |
Claim 5-specific avoidable; Claim 4 still covers many carriers |
Must still satisfy the ordered-mixture + particle-size-class elements |
| Remove micronized lactose with ≥50% ≤10 μm |
Avoids Claim 6/13 |
Claim 1 may remain infringed |
How strong is the patent estate for moisture-resistant DPI ordered mixtures with magnesium stearate?
Using Claim 1 structure as a proxy for strength:
- Strength driver 1: component and dose precision. The magnesium stearate identity plus dose range is clear and testable.
- Strength driver 2: particle-size-class framing. “Noninhalable” vs “inhalable” is a functional classifier that can be tested with PSD.
- Strength driver 3: ordered mixture as an additional distinguishing feature. It can differentiate from prior art “simple blends,” but it also raises proof burdens for the patentee.
What cannot be established from the text provided: whether the patent is accompanied by a broad specification that defines ordered-mixture processing in a forgiving way, or whether the claims are supported by strong experimental evidence. Those factors govern validity and enforceability but are not determinable from claim text alone.
Patent landscape and litigation status for U.S. Patent 6,645,466: what is known from the record provided?
The prompt provides claim text only and does not provide:
- the patent’s filing/grant dates,
- assignee or inventor identity,
- prosecution history,
- citation/forward-citation mapping,
- reexamination, terminal disclaimers, or continuation family links,
- or any litigation docket information.
Given those constraints, a complete landscape summary (including competitor challenge patterns, Paragraph IV activity tied to these specific claim structures, and Orange Book status for corresponding products) cannot be produced from the provided materials.
Accordingly, only claim-scope analysis is performed here, not an asserted-coverage or competitor-litigation map.
Key Takeaways
- U.S. Patent 6,645,466 protects a dry powder inhalation ordered-mixture formulation combining (i) a non-inhalable-size carrier, (ii) an inhalable-size active from the formoterol/ipratropium/tiotropium list and salts, and (iii) magnesium stearate at 0.1 to 2% w/w positioned to deliver improved moisture resistance.
- The most enforceable “core” is the architecture + particle-size class pairing + magnesium stearate identity and dosing. Dependent claims add narrower constraints on specific carriers (glucose/lactose monohydrate/trehalose) and micronized lactose monohydrate PSD (≥50% ≤10 μm).
- The strongest literal mapping is likely for lactose monohydrate DPI using formoterol salts with magnesium stearate at 0.4–0.8% w/w, and where manufacturing supports an ordered-mixture concept.
- Design-around strategies typically target one of the anchor elements: magnesium stearate identity/dose, particle-size regime assignments, carrier architecture, or ordered-mixture processing.
FAQs
- How does the “inhalable particle size” and “noninhalable particle size” language affect testing for DPI infringement?
- If a product uses magnesium stearate for lubrication but at 0.09% w/w, does it avoid Claim 1?
- Does Claim 6 require micronized lactose monohydrate specifically, or can a different micronized carrier satisfy the dependent limitation?
- Are formoterol tartrate and formoterol fumarate both covered equally under the salt-dependent branches?
- If the formulation meets all elements except “ordered mixture,” what evidence usually decides infringement?
References
No sources were cited because the response was limited to the claim text provided in the prompt.
